Bipolar Androgen Therapy + Carboplatin in mCRPC
The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
Trial Details
- NCT ID
- NCT03522064
- Phase
- PHASE2
- Sponsor
- St Vincent's Hospital, Sydney
- Status
- RECRUITING
- Cancer Type
- Prostate Cancer
- Interventions
- Testosterone Enanthate 100 MG/ML Injectable Solution
- Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
- Locations (sample)
- Sydney, New South Wales, Australia|-33.86785,151.20732
Key Eligibility Criteria
- Males with histologically confirmed adenocarcinoma of the prostate
- Confirmed HRD (Homologous recombination defect) in germline and/or somatic DNA analysis (tumour or blood), by a validated assay (see Appendix 1). M…
- Age ≥ 18 years
- ECOG performance status ≤ 1
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →